LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.
Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.
The program is set to begin proof-of-concept testing in the coming months, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.